Lincoln Pharma seems pretty good from numbers perspective.
- No Debt
- Growing topline. Management has openly targeted Rs. 750Cr topline by FY26 from Current ~550Cr in TTM Dec, 23.
- Historically Dividend paying company
- CFO more or less in line with PAT
- ROE 16-17% consistently
- Minimal related party transactions.
Currently trading at 13.3x PE and 2.13xPB.
I am wondering why this company should not trade at >20PE.
Invested and increasing allocation.